Trials / Completed
CompletedNCT04428502
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
Correlation of Anti-CCP With Disease Activity and Its Impact on Biological Response in PsA in Iraqi Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 127 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Teaching Hospital registry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enbrel | As provided in real world practice |
Timeline
- Start date
- 2020-07-05
- Primary completion
- 2020-08-30
- Completion
- 2020-08-30
- First posted
- 2020-06-11
- Last updated
- 2021-09-14
- Results posted
- 2021-09-14
Locations
1 site across 1 country: Iraq
Source: ClinicalTrials.gov record NCT04428502. Inclusion in this directory is not an endorsement.